Transplantation of human amniotic mesenchymal stem cells promotes neurological recovery in an intracerebral hemorrhage rat model

Zhou, Honglong; Zhang, Hongri; Yan, Zhongjie; Xu, Ran

doi:10.1016/j.bbrc.2016.05.075

Cited by 33 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Characterization of marker expression of stem cells was realized using the Fluorescence-activated cell sorting (FACS) method [23,24]). hAMSCs were positive for many surface markers including CD44, CD90 and also positive for transcription factors such Oct-4, Rex1, whereas they were negative for CD34, CD45 and CD117 in agreement with previous reports [25][26][27]. This confirmed that Dual enzyme (collagenase II and DNAase I) also ensured high activity of hAMSCs.…”

Section: Isolation and Primary Culture Of Hamscssupporting

confidence: 90%

Enhanced efficiency in isolation and expansion of hAMSCs via dual enzyme digestion and micro-carrier

Gohi

Liu

et al. 2020

Cell Biosci

View full text Add to dashboard Cite

A two-stage method of obtaining viable human amniotic stem cells (hAMSCs) in large-scale is described. First, human amniotic stem cells are isolated via dual enzyme (collagenase II and DNAase I) digestion. Next, relying on a culture of the cells from porous chitosan-based microspheres in vitro, high purity hAMSCs are obtained in large-scale. Dual enzymatic (collagenase II and DNase I) digestion provides a primary cell culture and first subculture with a lower contamination rate, higher purity and a larger number of isolated cells. The obtained hAMSCs were seeded onto chitosan microspheres (CM), gelatin-chitosan microspheres (GCM) and collagen-chitosan microspheres (CCM) to produce large numbers of hAMSCs for clinical trials. Growth activity measurement and differentiation essays of hAMSCs were realized. Within 2 weeks of culturing, GCMs achieved over 1.28 ± 0.06 × 10 7 hAMSCs whereas CCMs and CMs achieved 7.86 ± 0.11 × 10 6 and 1.98 ± 0.86 × 10 6 respectively within this time. In conclusion, hAMSCs showed excellent attachment and viability on GCM-chitosan microspheres, matching the hAMSCs' normal culture medium. Therefore, dual enzyme (collagenase II and DNAase I) digestion may be a more useful isolation process and culture of hAMSCs on porous GCM in vitro as an ideal environment for the large-scale expansion of highly functional hAMSCs for eventual use in stem cell-based therapy.

show abstract

Section: Isolation and Primary Culture Of Hamscssupporting

confidence: 90%

Enhanced efficiency in isolation and expansion of hAMSCs via dual enzyme digestion and micro-carrier

Gohi

Liu

et al. 2020

Cell Biosci

View full text Add to dashboard Cite

show abstract

“…In a study, hAMSCs promoted neurological recovery in rats after intracranial hemorrhage. It was concluded that the mechanism of action was mediated by inhibition of inflammation and apoptosis, increasing neurotrophic factors expression, and promoting neurogenesis and angiogenesis (54). hAMSCs induce differentiation of progenitor cells to neurons (52).…”

Section: Supporting Evidence For Hypothesismentioning

confidence: 99%

Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation

et al. 2019

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an inflammatory and degenerative disorder of the central nervous system with unknown etiology. It is accompanied by demyelination of the nerves during immunological processes in the presence of oxidative stress, hypoxia, cerebral hypo-perfusion, and dysregulation in matrix metalloproteinases (MMPs). Human amniotic mesenchymal stem cells (hAMSCs) as pluripotent stem cells possess some conspicuous features which could be of therapeutic value in MS therapy. hAMSCs could mimic the cascade of signals and secrete factors needed for promoting formation of stable neovasculature and angiogenesis. hAMSCs also have immunomodulatory and immunosuppressive effects on inflammatory processes and reduce the activity of inflammatory cells, migration of microglia and inhibit recruitment of certain immune cells to injury sites. hAMSCs attenuate the oxidative stress supported by the increased level of antioxidant enzymes and the decreased level of lipid peroxidation products. Furthermore, hAMSCs enhance neuroprotection and neurogenesis in brain injuries by inhibition of inflammation and promotion of neurogenesis. hAMSCs could significantly increase the expression of neurotrophic factors, which prevents neurons from initiating programmed cell death and improves survival, development, and function of neurons. In addition, they induce differentiation of neural progenitor cells to neurons. hAMSCs could also inhibit MMPs dysregulation and consequently promote the survival of endothelial cells, angiogenesis and the stabilization of vascular networks. Considering the mentioned evidences, we hypothesized here that hAMSCs and their conditioned medium could be of therapeutic value in MS therapy due to their unique properties, including immunomodulation and inflammation suppression; angiogenesis promotion; oxidative stress inhibition; neurogenesis induction and neuroprotection; matrix metalloproteinases regulation; and remyelination stimulation.

show abstract

“…Once administered, the engraftment and differentiation of MSCs into other cell types was assessed. BM-MSCs 30 and fetal/neonatal tissue derived-MSCs 39,43,44 were found in the ipsilateral cortex and around the lesion area after intracerebral injection, suggesting that transplanted MSCs are capable of surviving in the perilesional space. Moreover, migration of BM-MSCs to perihematomal sites was observed following intranasal delivery after ICH.…”

Section: Introductionmentioning

confidence: 98%

Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research

et al. 2019

View full text Add to dashboard Cite

Summary Significant progress has been made during the past few decades in stem cell therapy research for various diseases and injury states; however this has not been overwhelmingly translated into approved therapies, despite much public attention and the rise in unregulated ‘regenerative clinics’. In the last decade, preclinical research focusing on mesenchymal stem/stromal cell (MSC) therapy in experimental animal models of hemorrhagic stroke has gained momentum and has led to the development of a small number of human trials. Here we review the current studies focusing on MSC therapy for hemorrhagic stroke in an effort to summarize the status of preclinical and clinical research. Preliminary evidence indicates that MSCs are both safe and tolerable in patients, however future randomized controlled trials are required to translate the promising preclinical research into an effective therapy for hopeful patients.

show abstract

Transplantation of human amniotic mesenchymal stem cells promotes neurological recovery in an intracerebral hemorrhage rat model

Cited by 33 publications

References 27 publications

Enhanced efficiency in isolation and expansion of hAMSCs via dual enzyme digestion and micro-carrier

Enhanced efficiency in isolation and expansion of hAMSCs via dual enzyme digestion and micro-carrier

Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation

Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research

Contact Info

Product

Resources

About